Next Article in Journal
Malignant Melanoma Metastatic to the Larynx: Treatment and Functional Outcome
Previous Article in Journal
Severe Raynaud Syndrome Induced by Adjuvant Interferon Alfa in Metastatic Melanoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 17
Issue 4
10.3747/co.v17i4.526
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Aplastic Anemia with Concurrent Temozolomide Treatment in a Patient with Glioblastoma Multiforme

by
Jiwon Oh
1,*,
G. J. Kutas
2,
P. Davey
3,
M. Morrison
2 and
J. R. Perry
1
1
Division of Neurology, Department of Medicine, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
2
Medical Oncology, Department of Medicine, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
3
Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2010, 17(4), 124-126; https://doi.org/10.3747/co.v17i4.526
Submission received: 5 May 2010 / Revised: 9 June 2010 / Accepted: 8 July 2010 / Published: 1 August 2010

Abstract

Temozolomide (tmz) is an oral alkylating agent used during concurrent and adjuvant chemotherapy for newly diagnosed glioblastoma multiforme. Temozolomide is generally well tolerated and improves survival; however, severe adverse events have occasionally been reported. Here, we report the case of a patient who developed aplastic anemia with related complications in the setting of concurrent tmz treatment with radiotherapy. This case illustrates that aplastic anemia is a rare side effect of tmz that can occur relatively early in the course of concurrent chemotherapy, and underscores the importance of clinician awareness of this potentially devastating side effect.
Keywords: glioblastoma multiforme; temozolomide; pancytopenia; aplastic anemia glioblastoma multiforme; temozolomide; pancytopenia; aplastic anemia

Share and Cite

MDPI and ACS Style

Oh, J.; Kutas, G.J.; Davey, P.; Morrison, M.; Perry, J.R. Aplastic Anemia with Concurrent Temozolomide Treatment in a Patient with Glioblastoma Multiforme. Curr. Oncol. 2010, 17, 124-126. https://doi.org/10.3747/co.v17i4.526

AMA Style

Oh J, Kutas GJ, Davey P, Morrison M, Perry JR. Aplastic Anemia with Concurrent Temozolomide Treatment in a Patient with Glioblastoma Multiforme. Current Oncology. 2010; 17(4):124-126. https://doi.org/10.3747/co.v17i4.526

Chicago/Turabian Style

Oh, Jiwon, G. J. Kutas, P. Davey, M. Morrison, and J. R. Perry. 2010. "Aplastic Anemia with Concurrent Temozolomide Treatment in a Patient with Glioblastoma Multiforme" Current Oncology 17, no. 4: 124-126. https://doi.org/10.3747/co.v17i4.526

Article Metrics

Back to TopTop